Advertisement

Topics

AstraZeneca Collaboration to Target Breast and Lung Cancer Research

09:18 EDT 21 Aug 2017 | PharmPro

Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of patient-derived xenograft (PDX) models. The models will be used in AstraZeneca's oncology R&D programs in breast and lung cancer.
Contributed Author: 
Champions Oncology, Inc.

Original Article: AstraZeneca Collaboration to Target Breast and Lung Cancer Research

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca Collaboration to Target Breast and Lung Cancer Research"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...